AIM Vaccine's mRNA Shingles Shot Approved in China and the U.S.

The Booming U.S. Vaccines Market Size Trends and Projections

The U.S. vaccines market, valued at USD 29.5 billion in 2024, is set for robust growth, reaching USD 60 billion by 2033. Driven by rising demand, advancements in vaccine technology like mRNA, and increasing awareness about the importance of immunization, this market plays a vital role in public health. Challenges such as vaccine hesitancy and supply chain disruptions persist, necessitating focus on education and accessible services. As the lands…

AIM Vaccine's mRNA Shingles Shot Approved in China and the U.S.

HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine has received clinical trial approval from PRC's Center for Drug Evaluation (CDE), following its U.S. FDA clearance in March this year. The vaccine has …